Prana Biotechnology Ltd (ASX: PBT, NASDAQ: PRAN) (“Prana” or “the Company”) has today announced the US Food and Drug Administration (FDA) has granted Orphan Drug designation for its lead...
Life Biosciences LLC leads strategic investment of up to A$44.5 million (US$31.4 million) in Prana PR Newswire MELBOURNE, Australia and SAN FRANCISCO, Jan. 2, 2019 MELBOURNE, Australia and SAN...
PBT434 prevents alpha-synuclein aggregation, preserves neurons, reduces glial cell inclusions and slows motor dysfunction in an animal model of Multiple System Atrophy Prana Biotechnology...
Prana’s PBT434 prevents neuronal loss in a new model of neurodegeneration Prana Biotechnology Ltd (ASX PBT: NASDAQ PRAN) has today announced it will be presenting further pre-clinical...
Highlights: Prana enrols and doses its first cohort of healthy volunteers in its Phase I clinical trial Evidence supports activity of PBT434 to prevent α-synuclein accumulation...
Highlights: Prana receives ethics committee approval for a clinical trial evaluating first in human dosing of PBT434 Recruitment has commenced for the first cohort of healthy...
PBT434, Prana’s lead drug in preclinical development for movement disorders, to be profiled in collaborative venture Prana Biotechnology Ltd (ASX:PBT)(NASDAQ:PRAN) today announced a...
Scientific Journal Acta Neuropathologica publishes pre-clinical data Prana Biotechnology Ltd (NASDAQ: PRAN) (ASX: PBT) today announced the article “The novel compound PBT434 prevents...
David Stamler, M.D., has joined Prana Biotechnology (ASX: PBT) (NASDAQ: PRAN) as Chief Medical Officer and Senior Vice President, Clinical Development, based in San Francisco. Prior to...
Prana Biotechnology Ltd (ASX:PBT/NASDAQ:PRAN) is pleased to announce that further analysis of the cognitive results of its Reach2HD trial to treat Huntington Disease was presented in a...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.